Unlocking the next generation of complement therapies We are focused on stopping C1q, the initiating molecule of the classical complement pathway, at the start to treat devastating autoimmune, neurodegenerative, and ophthalmic diseases of the body, brain and eye. Our science We target C1q to block all damaging components of the immune system’s classical complement pathway. Learn more Our pipeline […]
Total raised: $78M
Founded date: 2011
Investors 3
| Date | Name | Website |
| 06.07.2021 | New Enterp... | nea.com |
| 17.07.2020 | Logos Capi... | logoscapit... |
| - | Bain Capit... | baincapita... |
Funding Rounds 2
| Date | Series | Amount | Investors | Deal News |
| 23.06.2016 | Series B | $44M | New Enterp... | citybizlis... |
| 15.12.2014 | Series A | $34M | - | finsmes.co... |
Mentions in press and media 11
| Date | Title | Description | Source |
| 13.11.2023 | Annexon Reports Significant Progress with its Priority Progr... | Company Prioritizes Greatest Near-term Value-Driving Programs: ANX005 for Guillain-Barré Syndrome (G... | einpresswi... |
| 08.01.2023 | Annexon Highlights Strategic Focus to Advance Four Flagship ... | Mid-stage and Pivotal Trials of ANX005, ANX007 and ANX1502 Poised to Achieve Numerous Catalysts in M... | einpresswi... |
| 02.07.2020 | Annexon grabs $100M from a host of top VC firms for compleme... | Annexon Biosciences has grabbed a healthy $100 million round to take its clinical work closer to the... | fiercebiot... |
| 19.12.2018 | Annexon Biosciences Closes $75M in Series C | SOUTH SAN FRANCISCO, CA, Clinical stage biopharmaceutical company announced that it has closed a $... | vcnewsdail... |
| 23.06.2016 | Biopharmaceutical Company Annexon Biosciences Closes $44M Se... | Annexon Biosciences, a South San Francisco, CA-based biopharmaceutical company developing classical ... | finsmes.co... |
| 23.06.2016 | Novartis Venture Fund Joins $44M Series B for Annexon Biosci... | SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Annexon Biosciences, a biopharmaceutical company pione... | citybizlis... |
| 23.06.2016 | NEA leads $44M round to get Stanford neurodegenerative spino... | Annexon Biosciences has snagged a major new VC to help back its ambitious, early neurodegenerative r... | fiercebiot... |
| 23.06.2016 | NEA Leads $44M Series B for Annexon Biosciences | SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Annexon Biosciences, a biopharmaceutical company pione... | citybizlis... |
| 31.03.2016 | New insight into Alzheimer’s suggests potential path to trea... | An immune process implicated earlier this year in schizophrenia may also cause the devastating brain... | statnews.c... |
| 15.12.2014 | Annexon Bioscience Closes $34M Series A-1 Funding Round | Annexon Bioscience, a Redwood City, Calif.-based developer of novel disease modifying drugs for neur... | finsmes.co... |
Show more